Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Simcere Pharmaceutical Buys Stake In Antitumor Firm

This article was originally published in PharmAsia News

Executive Summary

Simcere Pharmaceutical has announced that it is paying 64.82 million yuan ($9.2 million) to buy 70 percent stake in Anhui Zhongren Pharmaceutical, its third acquisition since listing in the U.S. last year. Anhui Zhongren specializes in the production of antitumor implant agents and is the developer of an innovative sustained-release fluorouracil implant that is unique in the market. One of Simcere's key strategies is to concentrate on core product acquisition and expansion; its latest purchase will enrich the firm's antitumor product portfolio as well as consolidate its leading position in the field. Company officials disclosed that some 800 million yuan ($114 million) has been allocated for future acquisitions. (Click here for more - Chinese language)

You may also be interested in...

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns

Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.

For Emergency Use, US FDA May Visit Rather Than Inspect COVID-19 Vaccine Manufacturing Sites

Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts